Generation of fully human anti-TNF antibody D2E7

被引：0
|
作者：
Salfield, J
Kaymakçalan, J
Tracey, D
Roberts, A
Kamen, R
机构：
[1] BASF Biores Corp, Worcester, MA USA
[2] Cambridge Antibody Technol Grp Plc, Melbourn, England
来源：
ARTHRITIS AND RHEUMATISM | 1998年 / 41卷 / 09期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
147
引用
收藏
页码：S57 / S57
页数：1
相关论文
共 50 条
  • [21] Safety and efficacy of adalimumab (D2E7), a fully human Anti-TNF-α monoclonal antibody, given in combination with standard antirheumatic therapy:: Safety trial of adalimumab in rheumatoid arthritis (STAR).
    Furst, DE
    Schiff, M
    Fleischmann, R
    Birbara, C
    Strand, V
    Compagnone, D
    Chartash, E
    ARTHRITIS AND RHEUMATISM, 2002, 46 (09): : S572 - S572
  • [22] Experiences with D2E7
    Rau, R
    Schattenkirchner, M
    van der Putte, L
    AKTUELLE RHEUMATOLOGIE, 2000, 25 (03) : 83 - 88
  • [23] A single dose, placebo controlled study of the fully human anti-tumor necrosis factor-α antibody adalimumab (D2E7) in patients with rheumatoid arthritis
    den Broeder, A
    van de Putte, LBA
    Rau, R
    Schattenkirchner, M
    van Riel, PLCM
    Sander, O
    Binder, C
    Fenner, H
    Bankmann, Y
    Velagapudi, R
    Kempeni, J
    Kupper, H
    JOURNAL OF RHEUMATOLOGY, 2002, 29 (11) : 2288 - 2298
  • [24] Adalimumab (D2E7), a fully human anti-TNF-α monoclonal antibody, improved health-related quality of life in patients with active rheumatoid arthritis despite concomitant methotrexate therapy.
    Wellborne, F
    Keystone, EC
    Kivitz, A
    Greenwald, M
    Teoh, L
    Fischkoff, S
    Chartash, E
    ARTHRITIS AND RHEUMATISM, 2002, 46 (09): : S518 - S518
  • [25] Effect of a fully human anti-TNFα monoclonal antibody on the local and systemic expression of TNFα and IL-1β.
    Barrera, P
    Joosten, LAB
    den Broeder, AA
    van de Putte, LBA
    van den Berg, WB
    ARTHRITIS AND RHEUMATISM, 1999, 42 (09): : S75 - S75
  • [26] Abbott Laboratories is banking on D2E7
    Anon
    Chemical Market Reporter, 2002, 261 (25):
  • [27] Efficacy and safety of the fully human anti-tumour necrosis factor α monoclonal antibody adalimumab (D2E7) in DMARD refractory patients with rheumatoid arthritis:: a 12 week, phase II study
    van de Putte, LBA
    Rau, R
    Breedveld, FC
    Kalden, JR
    Malaise, MG
    van Riel, PLCM
    Schattenkirchner, M
    Emery, P
    Burmester, GR
    Zeidler, H
    Moutsopoulos, HM
    Beck, K
    Kupper, H
    ANNALS OF THE RHEUMATIC DISEASES, 2003, 62 (12) : 1168 - 1177
  • [28] TNF blockade by the fully human monoclonal antibody, adalimumab (D2E7), in the ARMADA trial results in decreases in serum matrix metalloproteinase (MMP) levels along with impressive clinical improvement in refractory RA patients.
    Furst, D
    Keystone, E
    Weinblatt, M
    Kavanaugh, A
    Weisman, M
    Fischkoff, S
    Chartash, E
    ARTHRITIS AND RHEUMATISM, 2001, 44 (09): : S215 - S215
  • [29] ANTI-TNF ANTIBODY PREVENTS DEVELOPMENT OF EAE
    SELMAJ, K
    RAINE, CS
    CROSS, AH
    JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY, 1991, 50 (03): : 294 - 294
  • [30] A one-step, competitive electrochemiluminescence-based immunoassay method for the quantification of a fully human anti-TNFα antibody in human serum
    Horninger, D
    Eirikis, E
    Pendley, C
    Giles-Komar, J
    Davis, HM
    Miller, BE
    JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 2005, 38 (04) : 703 - 708
12345